Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.
15984
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15984,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
company featured image

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.

 

Cantex’s pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed.

 

READ MORE

pipeline featured image

• DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)

 

• Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.

 

READ MORE

doctor viewing vaccine

April 2020 – Chimerix, Exclusive Licensee of Cantex’ Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19.
READ MORE

 

July 2019 – Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia.
READ MORE

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)